The Native Antigen Company Ltd

Activities: Ingredients

Trending Articles

  1. Autolus Therapeutics' CAR-T therapy, Aucatzyl, bags FDA approval for ALL Aucatzyl (obecabtagene autoleucel) is the first CAR-T therapy to receive FDA approval with no risk evaluation mitigation strategy requirement
  2. LEWA optimises Bachem's oligonucleotide production through inline dilution system This system allows for a flow rate of 2,500 L per hour, while also enabling flexible buffer production with varying flow rates
  3. AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
  4. Romaco showcases its solid dosage processing portfolio at CPHI & PMEC India The company will display its portfolio suitable for the granulation, tableting, and coating of pharmaceutical solids
  5. Evotec strikes up a deal with Monacum Partners to sell its Halle API manufacturing facility The CDMO faction of Evotec will now function as DAPIN GmbH, which will continue to specialise in end-to-end chemical API development and manufacturing

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

Related Content

Drug Delivery

The Native Antigen Company strengthens senior team to support growing product portfolio

Appointments of Business Development Manager and Senior Product Manager follow move to state-of-the-art new facilities at Oxford Technology Park
Research & Development

Native Antigen Company expands range of norovirus-like particles

Norovirus is a small non-enveloped, positive-sense RNA virus belonging to the Caliciviridae family. It is a major cause of non-bacterial acute gastroenteritis outbreaks
Ingredients

The Native Antigen Company introduces veterinary reagents

The range includes pathogens such as coronaviruses, Borrelia, Rift Valley fever virus, African swine fever virus, Toxocara and heartworm
Manufacturing

The Native Antigen Company launches SARS-CoV-2 antibodies

The introduction of these antibodies extends The Native Antigen Company’s existing range and offers researchers a source of reagents for research
Ingredients

The Native Antigen Company introduces custom service for influenza antigens

The reagent supplier has announced the introduction of its custom contract service to rapidly develop antigen panels for influenza A and B viruses
Research & Development

BBI Solutions partners to distribute COVID-19 antigens in China

The Native Antigen Company has agreed distribution rights with BBI to provide coronavirus reagents in China
Ingredients

The Native Antigen Company introduces novel coronavirus antigen

UK company has developed rapid response manufacturing capabilities to produce reagents for emerging epidemic diseases
Subscribe now